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012.11.0Abstract Aims: The aim was to determine the relationship between apolipoprotein E (ApoE) gene
polymorphisms and lipid proﬁle in patients with coronary artery diseases (CAD), and its role in the
prediction of the severity of carotid and coronary atherosclerosis.
Methods and results: One hundred patients were classiﬁed by coronary angiography: 80 patients
with CAD and 20 controls (normal coronary angiography). Clinical data, carotid sonography, blood
lipid proﬁles and ApoE genotyping (PCR-RFLP) were assessed. CAD patients had signiﬁcantly
increased plasma lipid proﬁles and carotid intimal-wall thickness (IMT) versus controls. In CAD
patients; ApoE genotype frequencies were E3/E3 = 62.50%, E2/E3 = 18.75%, E3/E4 = 17.50%,
E2/E4 = 1.25%, E4/E4 = 0 and E2/E2 = 0. But, E3/E4 genotype was signiﬁcantly higher than con-
trols (P< 0.05). Also, in CAD patients; ApoE allele frequencies were E3 = 80.6%, E2 = 10.0%
and E4 = 9.4% but, ApoE4 alleles were associated with higher cholesterol (P= 0.034) and LDL-
c (P= 0.003), while ApoE2 alleles were associated with higher triglycerides (P= 0.037) versus
ApoE3 alleles. However, odds ratio of CAD patients had higher risk with E2/E3 genotypes (2.5-
fold), E2 alleles (2.2-fold) and E4 alleles (2.1-fold). Moreover, CAD patients with ApoE4 alleles
had signiﬁcantly higher carotid IMT (1.23 ± 0.26 mm vs 0.97 ± 0.2 mm ApoE3, P= 0.006; how-
ever, non-signiﬁcant vs 1.10 ± 0.40 mm ApoE2 and also, ApoE2 vs ApoE3 alleles, P= 0.633)
and left anterior descending (LAD) coronary artery stenosis (vs ApoE3 alleles, P= 0.016).
Conclusion: Ischemic patients with carotid and coronary atherosclerosis had signiﬁcantly higher
integration of dyslipidemia and ApoE alleles (ApoE2 with hypertriglyceridemia and ApoE4 with
hypercholesterolemia and higher LDL-c). ApoE polymorphism may be an important diagnostic risk
biomarker and may implicate therapeutic intervention in atherosclerotic ischemic patients.
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021. Introduction
Coronary artery disease (CAD) is the leading cause of death
and premature disability. CAD is a complex disorder resulting
from many risk factors. Individuals with genetic predisposition
to atherosclerosis have substantial risk of developing CAD,
especially at early ages.1,2 While it is difﬁcult to explore theg by Elsevier B.V. All rights reserved.
72 I. Elmadbouh et al.relationship between local vessel wall function and CAD sever-
ity, measuring DNA variants such as ApoE polymorphisms
may provide a way to assess this link because of its known ef-
fect on endothelial cell proliferation.3 ApoE gene is located at
chromosome 19q13.2, and consists of 4 exons and 3 introns
spanning 3597 nucleotides, and produces a 299 amino acid
polypeptide with a molecular mass of about 34 kDa.4
The genetic polymorphism of ApoE results from the
existence of 3 common co-dominant alleles (E2, E3, and E4
isoforms) that code for 3 apolipoproteins, resulting in 6 com-
mon genotypes (E2E2, E2E3, E2E4, E3E3, E3E4, and
E4E4).5 The most frequent isoform E3 contains a cysteine at
residue 112 and an arginine at residue 158, E2 and E4 differ
from the E3 isoform in that the E2 isoform contains a cysteine
at residue 158 and the E4 contains an arginine at residue 112.6
Apolipoprotein E (ApoE) is a plasma glycoprotein and
helps lipoprotein clearance from circulation.7 ApoE is a struc-
tural protein of chylomicrons, very-low-density lipoproteins,
intermediate-density lipoproteins, and high-density lipopro-
teins, and serves as a ligand for the uptake of ApoE-containing
lipoproteins by the hepatic ApoE receptor or low-density lipo-
protein (LDL) receptor.6 Owing to the complexity of the apoE
structure–function, it is not surprising that mutations and
polymorphisms of the ApoE gene can have an important im-
pact on protein function. The receptor binding properties of
ApoE are strongly inﬂuenced by isoform speciﬁc amino acid
differences as well as the lipidation state of the protein.7
ApoE3 and ApoE4 bind with similar afﬁnity, while, ApoE2
has just 2% of this binding afﬁnity resulting in dysfunctional
lipoprotein metabolism producing atherosclerosis.8
ApoE gene polymorphisms are associated with atheroscle-
rosis and play critical roles in lipid metabolism.3 It may account
for 2–16% of the variability of LDL cholesterol levels.9 Individ-
uals with different ApoE genotypes have different susceptibili-
ties to CAD.10Moreover, ApoE is the only one to have shown a
convincing association with carotid intima media thickness
(IMT).11 According to meta-analysis study, phenotypes of
ApoE and CAD were frequently different with ethnic differ-
ences in the studied populations in the world.3,12 The present
study was carried out to determine the relationship of ApoE
gene polymorphism with lipid proﬁles in patients with CAD de-
ﬁned by coronary angiography and its role in the prediction of
the severity of carotid and coronary atherosclerosis.2. Subjects and methods
2.1. Subjects
All the patients were consecutively referred to coronary inten-
sive care unit of the Department of Cardiology in the Meno-
uﬁya University Hospital and the Shebin Elkom Teaching
Hospital due to an acute myocardial infarction (MI) and
who underwent coronary angiography during follow up peri-
ods (from Sept. 2009 to June 2011) in this crosssectional study.
This study was carried out on 100 CAD patients: 80 CAD pa-
tient groups who had coronary artery stenosis in at least one of
the major coronary vessels; 20 control patient groups who
underwent angiography procedures and had normal coronar-
ies (with acute chest pain other than coronary diseases). There-
fore, the age and gender of patients were not matched in both
groups.Full history, general and heart clinical examination, carotid
ultrasound and blood samples were done for every patient.
Written informed consent was obtained from each participant
before inclusion in the study. Ethical approval for this investi-
gation was obtained from the Research Ethics Committee,
Faculty of Medicine, Menouﬁya University.
The excluding criteria for enrollment into the study in-
cluded familial hypercholesterolemia, cancer, renal disease,
and any other chronic illnesses.
2.2. Carotid ultrasound examination
Carotid artery examination was performed with an ECG-trig-
gered echo-Doppler Acuson 128 XP 10C equipped with a 7.5-
MHz linear transducer. Data collected from the right common
carotid artery were used for statistical analysis. A preliminary
scan veriﬁed the presence of plaques and/or stenosis in the car-
otid tree. Carotid parameters were measured such as carotid
intima media thickness (IMT), carotid systolic and diastolic
diameters and carotid systolic and diastolic velocities.11,13,14
2.3. Determination of CAD severity
According to the results of the coronary angiography, number
and percentage of stenosed coronary vessels were classiﬁed as
previously published.10 The characteristics of diseased vessels
were recorded, including the severity of the most serious steno-
sis (675% or >75%) and the number of diseased vessels (1, 2,
or 3 vessels) including the left main coronary artery (main
trunk), circumﬂex artery (LCA), right coronary artery
(RCA) and anterior descending artery (LAD). Also, the coro-
nary artery scoring was performed in order to evaluate the
severity of atherosclerosis providing a numerical value for le-
sions. The severity of CAD was determined using scoring
methods15 as follows severity numbers of normal vessel, coro-
nary lesion with <50%, 50–75%, 76–89%, 90–99%, 100%
luminal stenosis were 0, 10, 15, 20, 25 points, respectively.
2.4. Lipid proﬁles analysis
Venous blood sample (5 ml) from an overnight fasting patient
was taken for the determination of serum total cholesterol
(TC), triglycerides (TG) and HDL-C levels. Lipid proﬁles were
measured by the standard enzymatic colorimetric kits (SPIN-
REACT, Spain). The serum LDL-c was calculated by this for-
mula16 as TG level did not exceed 400 mg/dl: LDL-c = total
cholesterol – (TG/5 + HDL-c).
2.5. DNA analysis
Venous blood sample (5 ml) was drained slowly into a vacu-
nated EDTA tube for the isolation of peripheral blood mono-
nuclear cells (PBMCs) using Lymphoﬂot solution (Bio Test
AG, Germany). Brieﬂy, 5 ml of patient blood was added to
an equal volume of saline and mixed carefully. This diluted
blood sample was carefully layered onto the Lymphoﬂot solu-
tion (Sodium diatrizoate 11.00% and Ficoll 6.35% w/v) so as
not to mix the Lymphoﬂot solution and the diluted blood sam-
ple. The mixture was centrifuged at 1500 rpm for 25 min at
20C. The upper plasma layer was drawn off, leaving the lym-
phocyte layer undisturbed at the interface. The lymphocyte
layer at the interface was transferred to a clean centrifuge tube
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centrifuged at 1500 rpm for 10 min at 4C. The supernatant
was discarded. 1 ml of phosphate buffer saline (PBS) was
added to the lymphocytes’ pellet, drawn in and out of a clean
pipette and transferred into a sterile cryotube and stored at
80C for further DNA extraction and puriﬁcation.
Genomic DNA was extracted from PBMCs using QIAamp
DNA Blood Mini Kits (QIAGEN, Germany), to yield pure
DNA and stored at 20C for direct ampliﬁcation. ApoE
polymorphism was detected by the polymerase chain reaction
(PCR) using Perkin Elmer thermal cycler 2400 (USA).
The DNA was ampliﬁed using the following primers
(Midland, Texas) forward primer, 50TCCAAGGAGCTGC
AGGCGGCGCA-30; reverse primer, 50GCCCCGGCCTGGT
ACACTGCCA-30. DNA – ApoE band (218 bp) was shown
clearly under protocol (denaturation for 1 min at 94C, anneal-
ing for 1: 30 min at 60C, extension for 1: 30 min at 72C, 40
cycles).
ApoE gene typing was done by restriction fragment length
polymorphism (RFLP). The PCR bands (218 bp) were di-
gested by two restriction enzymes such as Hae II (2000 unit)
and Aﬂ III (250 unit) restriction endonucleases (Biolabs,
New England) in 25 ll working solution containing 2.5 ll of
10· buffer, 0.25 ll of 100· BSA, 0.5 ll of Hae II, 0.5 ll of
Aﬂ III, 6.25 ll of distilled water and 15 ll of PCR product
for at least 24 h at 37C. The presence of ApoE polymor-
phisms bands was detected in 4% agarose gel electrophoresis
visualized under UV light. ApoE alleles appeared: E2 at
168 bp, E3 at 145 bp and E4 at 195 bp.
2.6. Statistical analysis
Variables are presented as numbers, percentages (%) or
mean ± standard deviation (SD), as indicated. Genotypes
and allele frequencies of ApoE were compared between CAD
cases and controls using Chi-Square (v2) test or Fisher’s exact
test, as indicated. Student’s t-test and ANOVA were used to
compare means, as indicated. All Odds ratios were calculated
by logistic regression. All tests were 2 tailed and a P value
of < 0.05 was considered as being statistically signiﬁcant. Re-
sults were analyzed by statistical software package SPSS ver-
sion 11.
3. Results
The present study showed signiﬁcantly higher age, male,
smoking, hypertension, diabetes, total cholesterol, triglycer-
ides, LDLc, while lower HDLc in CAD patients versus controls
(Table 1). Also, there was a signiﬁcant difference between CAD
patients and control with regard to ultrasound carotid IMT
(P< 0.001), diastolic diameter (P= 0.004), systolic velocity
(P= 0.024) and plaque number (P< 0.001), while carotid sys-
tolic diameter (P= 0.165) and diastolic velocity (P= 0.655)
were not signiﬁcant between the two groups (Table 1).
The distribution of ApoE genotypes and ApoE alleles in
CAD patients versus control were in CAD patients (E3/
E3 = 62.50%, E2/E3 = 18.75%, E3/E4 = 17.50%, E2/
E4 = 1.25%, E4/E4 = 0.0% and E2/E2 = 0.0%). Also, ApoE
alleles frequencies were E3 = 80.6%, E2 = 10.0% and
E4 = 9.4% (Fig. 1). Only the E3/E4 genotype was statistically
signiﬁcant (17.5% vs 0.0%, P< 0.05) in CAD patientscompared to the control, while there was no signiﬁcant differ-
ence between the CAD patients and control with other ApoE
genotypes. E2 alleles (10.0% vs 5%, P> 0.05) and E4 alleles
(9.4% vs 5%, P> 0.05) were not signiﬁcantly higher between
CAD patients and control (Fig. 1). Odds ratio (OR) for E2/
E3 genotype, E2 and E4 alleles were 2.55 (95% CI = 0.53–
12.31, P< 0.05), 2.23 (95% CI = 0.49–10.16, P> 0.05) and
2.09 (95% CI = 0.46–9.58, P> 0.05) respectively, while we
could not calculate the risk of E3E4 genotype by odds ratio
as there was no E3E4 genotype in the control. The present
study showed that there was no signiﬁcant difference between
E2, E3 and E4 phenotypes as regards age, sex, smoking, hyper-
tension and diabetes (Data not shown).
Echocardiographic data of CAD patients, E4 allele had
signiﬁcantly higher carotid IMT (P= 0.006) versus E3 alleles
(Fig. 2). Also, there was no signiﬁcant difference between E2,
E3 and E4 phenotypes as regards carotid diameter and velocity
in systolic and diastolic phases, and number of carotid plaques
(Fig. 2). The study also showed that E3 allele had signiﬁcantly
higher carotid diastolic diameter in patients than E3 allele in
the control (Fig. 2).
Lipid proﬁles analysis: Apo E4 allele was signiﬁcantly asso-
ciated with higher total cholesterol and LDLc than E3 alleles
in patient groups, while E2 allele was signiﬁcantly associated
with higher triglyceride versus E3 alleles in patient groups.
There was no signiﬁcant difference between E2, E3 and E4 al-
leles as regards HDLc (Fig. 3).
Severity of coronary artery diseases were analyzed in Table
2. There was no signiﬁcant difference between E2, E3 and E4
alleles as regards the number of stenosed vessels and the per-
cent of stenosis. However, the E4 allele had a signiﬁcantly
higher percent of stenosis in the LAD coronary vessel
(P= 0.016) than E2 and E3 alleles in patient groups. E2 and
E4 alleles tend to have >75% stenosis (Odd Ratio: 1.88,
95% CI = 0.47 – 7.62; P> 0.05) when compared with the
E3 allele. There was no signiﬁcant difference between E2, E3
and E4 alleles as regards scoring system (P= 0.094) but, E4
allele still had the highest score (37.0 ± 22.26) compared to
E2 (33.66 ± 18.07) and E3 (27.40 ± 17.99).
4. Discussion
Alteration of blood lipid and lipoprotein biomarkers is
commonly present in CAD patients.2 Apolipoprotein polymor-
phisms at multiple genes have been associated with cardiovas-
cular disease, and considerable heterogeneity exists among
studies.17 This study investigated the role of polymorphisms
of ApoE gene in patients with CAD and probable differences
between genotypes for extent and severity scorings.
The present study showed signiﬁcantly higher age, male,
smoking, hypertension, diabetes, total cholesterol, triglycerides,
and LDLc, while lower HDLc in CAD patients versus controls.
These results were in agreement with others published showing
males, elderly,18 smokers, hypertensive and dyslipidemia as
classic risk factors in CAD patients.19 However, there was no
signiﬁcant difference between E2, E3 and E4 phenotypes as
regards age, sex, smoking, hypertension and diabetes. These
results were consistent with those reported previously.3,6,20
Our study showed that the frequency of E2E3 and E3E4
genotypes was higher in CAD patients as compared with the
control. These results were in agreement with other studies19,21
Table 1 Sociodemographic, carotid parameters and lipid proﬁles in all patients.
CAD patients n= 80 Controls n= 20 P value
Age (years) 55.48 ± 7.85 48.0 ± 8.36 <0.001
Sex no. (%)
Male 59 (73.8%) 7 (35.0%) <0.01
Female 21 (26.2%) 13 (65.0%)
Smoker no. (%)
Positive 12 (15.0%) 1 (5.0%) <0.01
Negative 32 (40.0%) 17 (85.0%)
Ex-smoker 36 (45.0%) 2 (10.0%)
Hypertensive no. (%)
Positive 60 (75.0%) 10 (50.0%) <0.05
Negative 20 (25.0%) 10 (50.0%)
Diabetic no. (%)
Positive 34 (42.5%) 0 (0.0%) <0.001
Negative 46 (57.5%) 20 (100.0%)
Carotid ultrasound
Intima media thickness (IMT) (mm) 1.04 ± 0.27 0.64 ± 0.12 <0.001
Systolic diameter (mm) 64.07 ± 6.64 61.35 ± 7.94 0.165
Diastolic diameter (mm) 58.46 ± 8.12 51.95 ± 7.78 0.004
Systolic velocity (cm/s) 36.53 ± 16.93 47.55 ± 18.37 0.024
Diastolic velocity (cm/s) 11.27 ± 4.95 10.70 ± 4.16 0.655
Plaque numbers 1.77 ± 1.39 0 ± 0 <0.001
Lipid proﬁles
Cholesterol (TC) (mg/dl) 172.76 ± 41.31 143.21 ± 34.39 <0.01
Triglyceride (TG) (mg/dl) 158.84 ± 96.24 89.48 ± 66.29 <0.01
HDLc (mg/dl) 33.53 ± 8.93 48.96 ± 9.80 <0.001
LDLc (mg/dl) 107.34 ± 37.0 76.37 ± 30.27 <0.01
Figure 1 PCR gel shows the length of ampliﬁed PCR fragment is 218 bp using a ladder of 100 bp (A); various ApoE genotypes (B) in a
sample of CAD patients (E2 at 168 bp, E3 at 145 bp and E4 at 195 bp); percentage of ApoE genotypes; (C) and alleles (D) in CAD patients
and the control respectively.
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quent22 and there was increased prevalence of E4/E4 and E2/
E4 genotypes
1 among patients with CAD.Moreover, our study revealed that the higher E4 allele fre-
quency in CAD patients versus controls was (9.4% vs 5%).
The results were the same as those reported in multi-centers;
Figure 2 (A) Echocardiographic data in the common carotid artery (CCA), intima media thickness (IMT) and atherosclerotic plaque
(A1) and systolic and diastolic velocities (A2) were shown. Carotid IMT (B), diameter (C and D) and velocity (E and F) in systolic and
diastolic phases respectively were shown in CAD patients and the control. (Mean ± SD).
Figure 3 Shows the relation of different alleles to cholesterol (A), triglycerides (B), HDLc (C) and LDLc (D) in CAD patients and the
control. (Mean ± SD).
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13.7%),24 Turkey (18.9% vs. 6.5%),25 Britain (26.7% vs.
11.3%),26 Iran (18.7% vs 3.3%)19 and India (15.1% vs
6.7%).21 It was observed that individuals who possess ApoE4
had more severe types of CAD and also experienced infarcts
with more frequently than others worldwide.3,12 According
to a meta-analysis study, carriers of ApoE4 allele had a 42%
higher risk for CAD compared to E3 allele carriers.1,3,18,27 In
contrast, others found that the association between E4 allele
and CAD was negative.12,18 The interplay between genetic
and environmental factors must be thoroughly considered in
order to evaluate the etiological role of Apo E in CAD. Indi-vidual variations and these discrepancies could be genetic het-
erogeneity and gene environment interactions in different
ethnic populations.12,18
Carotid atherosclerosis was considered a surrogate marker
for coronary atherosclerosis, and thus, the measurement of
IMT by ultrasound provides a quantitative basis for the extent
of atherosclerosis.28 The present study showed that increased
carotid IMT was signiﬁcantly associated in CAD patients ver-
sus controls. Also, among CAD patients, increased carotid
IMT was highly signiﬁcant with E4 allele versus E3 allele pa-
tients. However, in CAD patients, there was no signiﬁcant dif-
ference between E2, E3 and E4 phenotypes as regards the
Table 2 Different risk classiﬁcations using coronary angiography in different ApoE alleles among CAD patients.
ApoE alleles P value
E2
n= 15
E3
n= 50
E4
n= 15
Percentage of coronary vessels stenosis (%)
Main trunk 66.66 ± 15.27 50.0 ± 28.28 50.0 ± 0.0 0.374a
1.0b
LAD 78.21 ± 16.36 77.84 ± 21.22 86.15 ± 22.65 0.569a
0.016b
LCX 79.28 ± 19.66 67.96 ± 22.37 72.77 ± 23.33 0.265a
0.520b
RCA 73.18 ± 18.20 80.60 ± 22.74 82.33 ± 23.45 0.175a
0.615b
Number of stenosed vessels no. (%)
One 4 (26.7%) 16 (32.0%) 6 (40.0%) 0.059a
Two 4 (26.7%) 20 (40.0%) 2 (13.3%) 0.089b
Three 5 (33.3%) 14 (28.0%) 6 (40.0%)
Three + main trunk 2 (13.3%) 0 (0.0%) 1 (6.7%)
Number of stenosed vessels no. (%)
Single 4 (26.7%) 16 (32.0%) 6 (40.0%) 0.694a
Multiple 11 (73.3%) 34 (68.0%) 9 (60.0%) 0.565b
Percent of stenosis vessels
No. (%)c
675% 3 (20.0%) 16 (32.0%) 3 (20.0%) 0.370a
>75% 12 (80.0%) 34 (68.0%) 12 (80.0%) 0.370b
Scoring 33.66 ± 18.07 27.40 ± 17.99 37.0 ± 22.26 0.305a
0.094b
a Comparison between E3 and E2.
b Comparison between E3 and E4.
c Odds Ratio of E2 and E4 alleles tends to have >75% stenosis (1.88, 95% CI = 0.47–7.62; P> 0.05) when compared with the E3 allele.
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both systolic and diastolic phases. These results are consistent
with previous results.11,28,29 The inﬂuence of ApoE4 in the risk
of coronary disease modulated their inﬂuence in the risk of
carotid atherosclerosis. Increased arterial diameter in conjunc-
tion with wall thickness (arterial remodeling) might provide
useful information for understanding atherosclerosis progres-
sion, vascular injury or vascular vulnerability plaques.30 In
contrast, one study reported that ApoE4 phenotype was not
associated with increased carotid IMT and the number of car-
otid plaques,14,31 attributed these results to ethnic factors, gen-
der and environmental conditions.
The present study showed that ApoE4 allele was signiﬁ-
cantly associated with higher total cholesterol and LDLc versus
the E3 allele, while E2 allele was signiﬁcantly associated with
higher triglyceride versus the E3 allele. There was no signiﬁcant
difference between E2, E3 and E4 alleles as regards HDLc.
These results were consistent with previous publica-
tions.19,20,28,29 The E4 allele has been associated with higher lev-
els of total cholesterol and LDL cholesterol (LDLc), however
individuals with E2 allele tend to have lower total cholesterol
and LDLc levels in adults and children.16 The atherogenity of
the ApoE4was explained possibly by the high afﬁnity of ApoE4
toApoE binding receptors, leading to increasedApoEmediated
cholesterol uptake of liver cells (increased in the hepatic choles-
terol pool) and down-regulation of the LDL receptor (resulting
in accumulation of LDLc and increased risk of atherosclerosis).
Also, the recycling of ApoE originating from triglyceride rich
lipoprotein remnants was impaired in ApoE4 compared toApoE3 leading to decreased cholesterol efﬂux.28 ApoE allele
had speciﬁc antioxidant activity (ApoE2 > ApoE3 > ApoE4).
The association of ApoE4 allele with CAD severity could be due
to its default action in protecting lipoproteins from oxidative
damage as oxidized LDLc and its uptake bymacrophages could
lead to formation of foam cells which initiate the process of ath-
erosclerosis.1 In contrast, there was no signiﬁcant difference be-
tween the three phenotypes as regards all lipid parameters.3,6
Association of ApoE polymorphism with lipid trait might be re-
lated to gene-environmental interaction19 and/or increased
westernization.29
The current study showed that there was no signiﬁcant dif-
ference between E2, E3 and E4 phenotypes as regards the num-
ber, percentage and scoring of coronary stenosis. Our study
showed that E4 had signiﬁcant higher percentage of stenosis
in LAD vessels (vs other coronary arteries) compared with
E2 and E3. This indicated that E4 allele is associated with
severity of CAD as LAD vessels is one of the major coronary
vessels. However, E4 was non-signiﬁcantly higher in scoring
and above 75% stenosis of the coronary vessels. These results
were in agreement with previous studies.3,18 In contrast,
ApoE4 carriers had a signiﬁcantly higher number of diseased
vessels, more serious (>75% stenosis), more wide range vessel
disease and longer vessel disease, while ApoE2 carriers had
<75% stenosis and shorter vessel disease compared to E3E3
carriers.10 These associations with severity were mediated not
only by changes in circulating lipids, lipoproteins and apolipo-
proteins but also by other mechanisms in the population of
CAD. In contrast, another study reported that the E3 allele
Apolipoprotein E polymorphysim in ischemic heart 77is associated with more severe and the E2 allele is associated
with less severe disease.3 The lack of association could be ex-
plained in part by the fact that the frequency of this allele
was low in our sample and also to population differences.
Beyond the traditional association studies, the Apo E4 al-
lele has been shown in some studies to be associated with in-
creased response to dietary intervention. Conversely, APOE
E2 carriers appear to be more responsive to statin therapy.32
4.1. In conclusion
CAD patients had a signiﬁcantly higher integration of dyslipi-
demia and atherogenic ApoE alleles (E2 with hypertriglyceri-
demia and E4 with hypercholesterolemia and higher LDLc)
with carotid and coronary atherosclerosis. E2E3 and E3E4
genotypes and ApoE4 alleles were of higher frequencies in se-
vere CAD patients. These observations pay attention to the
role of ApoE gene as a diagnostic and may be a prognostic
marker of CAD severity, and may implicate therapeutic inter-
vention in ischemic heart patients.
Further, this observational interplay between genetic and
environmental factors must be thoroughly considered in order
to evaluate the etiological role of Apo E in CAD. These com-
plexities necessitate future research and seeking for different
mutations would help to understand the genetic background
of CAD.Acknowledgements
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